Wallsh J, Luths C, Kil H, et al. - In patients treated for retinal vein occlusion (RVO), diabetic macular edema (DME) or uveitis, researchers sought to assess the initial ten years of results from the intravitreal dexamethasone implant (DEX). The sample consisted of patients receiving DEX since its FDA approval. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography, intraocular pressure and cataract status have been obtained. A total of 315 eyes received 1216 DEX over 63.9 ± 4.6 weeks. According to this retrospective chart review, repeated DEX over extended follow-up provides significant anatomic benefits to all cohorts. Visual advantages are only seen in RVO, DME and select uveitis demographics.